TABLE 3.

A summary of current erosolized liposome formulations targeting EMT-markers in the literature.

NP	API(s)	Disease	Model(s)	Effect	Ref
Liposome	PGE2	Idiopathic pulmonary fibrosis (IPF)	IPF mice	Inhibition of TGFB-initiated pathways and TNF, restricted inflammation and fibrosis	Ivanova et al. (2013)
Liposome	Paclitaxel	Pulmonary fibrosis (PF)	PF mice	Inhibition of TGF-β1, reduced collagen levels and alveolar thickness	Zhou et al. (2016)
Liposome	Simvastatin + paclitaxel	Lung cancer	A549T mice	Inhibition of EMT and metastasis	Jin et al. (2019)
DPPE liposome	Hyaluronic acid	CTD-ILD + BOS	A549 + Calu-3 + THP-1 cells	Inhibition of VEGF mRNA	Pandolfi et al. (2019)

DPPE, 1,2-Bis(diphenylphosphino)ethane; CTD-ILD, connective tissue disease-associated interstitial lung disease; BOS, Bohring-Opitz Syndrome.